Lonza Group: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Infobox company | [[File:Lonza.svg|thumb]] [[File:Lonza Logo.svg|thumb]] [[File:Lonza Logo.svg|thumb]] {{Infobox company | ||
| name = Lonza Group | | name = Lonza Group | ||
| logo = | | logo = Lonza_Logo.svg | ||
| type = Public | | type = Public | ||
| traded_as = SIX: LONN | | traded_as = SIX: LONN | ||
| industry = Pharmaceuticals, Biotechnology | | industry = Pharmaceuticals, Biotechnology | ||
| founded = 1897 | | founded = 1897 | ||
| founder = Alexander von | | founder = Alexander von Hubel | ||
| headquarters = Basel, Switzerland | | headquarters = Basel, Switzerland | ||
| key_people = Pierre-Alain Ruffieux (CEO) | | key_people = Pierre-Alain Ruffieux (CEO) | ||
| Line 15: | Line 15: | ||
}} | }} | ||
'''Lonza Group''' is a leading global provider of integrated healthcare solutions, specializing in the development, manufacturing, and | '''Lonza Group''' is a leading global provider of integrated healthcare solutions, specializing in the development, manufacturing, and commercialization of pharmaceutical and biotechnology products. Founded in 1897 in the Swiss Alps, Lonza has grown to become a key player in the life sciences industry, with a focus on innovation and sustainability. | ||
==History== | ==History== | ||
Lonza was established in 1897 in the small Swiss town of Gampel, initially focusing on the production of electricity and calcium carbide. Over the years, the company expanded its operations and | Lonza was established in 1897 in the small Swiss town of Gampel, initially focusing on the production of electricity and calcium carbide. Over the years, the company expanded its operations into the chemical and pharmaceutical sectors. In the 1970s, Lonza shifted its focus towards biotechnology, which has since become a core component of its business strategy. | ||
In the | In 1999, Lonza was spun off from Alusuisse-Lonza Group Ltd and became an independent company listed on the Swiss Stock Exchange. Since then, Lonza has made several strategic acquisitions to enhance its capabilities in the life sciences sector, including the acquisition of Capsugel in 2017, a leader in capsule-based drug delivery solutions. | ||
==Operations== | ==Operations== | ||
Lonza operates through | Lonza operates through two main segments: Pharma & Biotech and Specialty Ingredients. | ||
===Pharma & Biotech=== | |||
The Pharma & Biotech segment focuses on the development and manufacture of active pharmaceutical ingredients (APIs), biopharmaceuticals, and cell and gene therapies. Lonza provides end-to-end solutions for its clients, from early-stage development to commercial manufacturing. The company is known for its expertise in mammalian cell culture, microbial fermentation, and chemical synthesis. | |||
===Specialty Ingredients=== | |||
The Specialty Ingredients segment offers a wide range of products, including microbial control solutions, personal care ingredients, and nutritional supplements. Lonza's microbial control solutions are used in various industries, such as water treatment, paints and coatings, and wood protection. | |||
==Research and Development== | ==Research and Development== | ||
Lonza invests significantly in research and development to drive innovation and maintain its competitive edge. The company collaborates with academic institutions, research organizations, and industry partners to advance its | Lonza invests significantly in research and development to drive innovation and maintain its competitive edge. The company collaborates with academic institutions, research organizations, and industry partners to advance its technological capabilities and develop new products. Lonza's R&D efforts are focused on areas such as biologics, cell and gene therapy, and sustainable chemistry. | ||
==Sustainability== | ==Sustainability== | ||
Lonza is committed to sustainability and | Lonza is committed to sustainability and has implemented various initiatives to reduce its environmental impact. The company aims to minimize waste, reduce energy consumption, and promote the use of renewable resources. Lonza also focuses on sustainable sourcing and ethical business practices. | ||
==Also see== | ==Also see== | ||
* [[Biotechnology]] | |||
* [[Pharmaceutical industry]] | * [[Pharmaceutical industry]] | ||
* [[Active pharmaceutical ingredient]] | * [[Active pharmaceutical ingredient]] | ||
* [[Biopharmaceutical]] | * [[Biopharmaceutical]] | ||
* [[Cell therapy]] | * [[Cell therapy]] | ||
* [[Gene therapy]] | * [[Gene therapy]] | ||
{{Pharmaceutical companies}} | {{Pharmaceutical companies}} | ||
Latest revision as of 15:21, 9 December 2024
Lonza Group
| Type | Public |
|---|---|
| Traded as | SIX: LONN |
| Key people | Pierre-Alain Ruffieux (CEO) |
| Industry | Pharmaceuticals, Biotechnology |
| Products | Active pharmaceutical ingredients, Biopharmaceuticals, Specialty chemicals |
| Revenue | CHF 4.5 billion (2020) |
| Employees | 15,000 (2020) |
| Website | [www.lonza.com Official website] |
Lonza Group is a leading global provider of integrated healthcare solutions, specializing in the development, manufacturing, and commercialization of pharmaceutical and biotechnology products. Founded in 1897 in the Swiss Alps, Lonza has grown to become a key player in the life sciences industry, with a focus on innovation and sustainability.
History[edit]
Lonza was established in 1897 in the small Swiss town of Gampel, initially focusing on the production of electricity and calcium carbide. Over the years, the company expanded its operations into the chemical and pharmaceutical sectors. In the 1970s, Lonza shifted its focus towards biotechnology, which has since become a core component of its business strategy.
In 1999, Lonza was spun off from Alusuisse-Lonza Group Ltd and became an independent company listed on the Swiss Stock Exchange. Since then, Lonza has made several strategic acquisitions to enhance its capabilities in the life sciences sector, including the acquisition of Capsugel in 2017, a leader in capsule-based drug delivery solutions.
Operations[edit]
Lonza operates through two main segments: Pharma & Biotech and Specialty Ingredients.
Pharma & Biotech[edit]
The Pharma & Biotech segment focuses on the development and manufacture of active pharmaceutical ingredients (APIs), biopharmaceuticals, and cell and gene therapies. Lonza provides end-to-end solutions for its clients, from early-stage development to commercial manufacturing. The company is known for its expertise in mammalian cell culture, microbial fermentation, and chemical synthesis.
Specialty Ingredients[edit]
The Specialty Ingredients segment offers a wide range of products, including microbial control solutions, personal care ingredients, and nutritional supplements. Lonza's microbial control solutions are used in various industries, such as water treatment, paints and coatings, and wood protection.
Research and Development[edit]
Lonza invests significantly in research and development to drive innovation and maintain its competitive edge. The company collaborates with academic institutions, research organizations, and industry partners to advance its technological capabilities and develop new products. Lonza's R&D efforts are focused on areas such as biologics, cell and gene therapy, and sustainable chemistry.
Sustainability[edit]
Lonza is committed to sustainability and has implemented various initiatives to reduce its environmental impact. The company aims to minimize waste, reduce energy consumption, and promote the use of renewable resources. Lonza also focuses on sustainable sourcing and ethical business practices.
Also see[edit]
- Biotechnology
- Pharmaceutical industry
- Active pharmaceutical ingredient
- Biopharmaceutical
- Cell therapy
- Gene therapy
| Pharmaceutical companies | ||||||
|---|---|---|---|---|---|---|
|
